IDE849 is a potential first-in-class DLL3 TOP1i antibody-drug conjugate for DLL3-upregulated solid tumors, with early efficacy signals in small-cell lung cancer cohorts. IDEAYA initiated a global Phase 1 program in May 2025 and has achieved first-patient-in in the United States. Development plans include expansion into neuroendocrine and other DLL3-overexpressing tumors.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07174583 |
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer |
RECRUITING | PHASE1/PHASE2 |
